MX376077B - Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2. - Google Patents
Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2.Info
- Publication number
- MX376077B MX376077B MX2015012547A MX2015012547A MX376077B MX 376077 B MX376077 B MX 376077B MX 2015012547 A MX2015012547 A MX 2015012547A MX 2015012547 A MX2015012547 A MX 2015012547A MX 376077 B MX376077 B MX 376077B
- Authority
- MX
- Mexico
- Prior art keywords
- receptor agonist
- trpv2 receptor
- cardiac dysfunction
- trpv2
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361778826P | 2013-03-13 | 2013-03-13 | |
| PCT/US2014/025930 WO2014160153A1 (en) | 2013-03-13 | 2014-03-13 | Treatment of a diastolic cardiac dysfunction with a trpv2 receptor agonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015012547A MX2015012547A (es) | 2016-02-10 |
| MX376077B true MX376077B (es) | 2025-03-07 |
Family
ID=50680137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015012547A MX376077B (es) | 2013-03-13 | 2014-03-13 | Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10583103B2 (enExample) |
| EP (1) | EP2968238A1 (enExample) |
| JP (3) | JP2016512564A (enExample) |
| AU (1) | AU2014244053B2 (enExample) |
| CA (1) | CA2904671C (enExample) |
| MX (1) | MX376077B (enExample) |
| WO (1) | WO2014160153A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
| EP3563859B1 (en) | 2012-08-13 | 2021-10-13 | Cedars-Sinai Medical Center | Cardiosphere-derived exosomes for tissue regeneration |
| CA2962444C (en) | 2014-10-03 | 2023-09-05 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
| EP3402543B1 (en) * | 2016-01-11 | 2021-09-08 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
| US11351200B2 (en) | 2016-06-03 | 2022-06-07 | Cedars-Sinai Medical Center | CDC-derived exosomes for treatment of ventricular tachyarrythmias |
| WO2018057542A1 (en) | 2016-09-20 | 2018-03-29 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders |
| EP3612191B1 (en) | 2017-04-19 | 2026-03-11 | Cedars-Sinai Medical Center | Methods and compositions for treating skeletal muscular dystrophy |
| AU2018384096B2 (en) * | 2017-12-12 | 2021-04-15 | Cardiol Therapeutics Inc. | Amphiphilic block copolymers, micelles, and methods for treating or preventing heart failure |
| US11660355B2 (en) | 2017-12-20 | 2023-05-30 | Cedars-Sinai Medical Center | Engineered extracellular vesicles for enhanced tissue delivery |
| EP3749344A4 (en) | 2018-02-05 | 2022-01-26 | Cedars-Sinai Medical Center | METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS |
| US12642806B2 (en) | 2019-10-25 | 2026-06-02 | Cardiol Therapeutics Inc. | Cannabidiol compositions for use in treating heart conditions |
| EP4106870A4 (en) * | 2020-02-19 | 2024-04-10 | Merchant, Shreema | Compositions and therapeutic uses of cannabidiol |
| KR20210150011A (ko) * | 2020-06-03 | 2021-12-10 | 주식회사 삼오파마켐 | 프로베네시드 및 아르기닌의 아미드 유도체, 이를 포함하는 약제학적 조성물 및 이의 제조 방법 |
| CN113861633B (zh) * | 2021-10-14 | 2022-12-20 | 武汉工程大学 | 一种p-n-b阻燃pbs塑料及其制备方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3524917A (en) | 1969-02-10 | 1970-08-18 | Merck & Co Inc | Tablets of magnesium probenecid tetrahydrate |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| JPH01211582A (ja) | 1988-02-16 | 1989-08-24 | Tanabe Seiyaku Co Ltd | ベンゾジオキソール誘導体 |
| CA2115442C (en) | 1991-09-09 | 2003-09-23 | Christopher Franklin Bigge | Pharmaceutical preparation containing an uricosuric agent and an excitatory amino acid antagonist |
| US5444067A (en) | 1993-08-30 | 1995-08-22 | Merck & Co., Inc. | Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety |
| US20030212123A1 (en) | 1997-05-05 | 2003-11-13 | Pfizer Inc. | COX-2 selective carprofen for treating pain and inflammation in dogs |
| US6221856B1 (en) | 1999-02-03 | 2001-04-24 | Inologic, Inc. | Inositol derivatives for inhibiting superoxide anion production |
| EP1317258B1 (en) | 2000-06-28 | 2009-02-11 | Merck & Co., Inc. | Use of allopurinol for the treatment of hypertension |
| AU2001227030A1 (en) | 2000-11-22 | 2002-06-03 | Lupin Laboratories Limited | Pharmaceutical composition for controlled release of an active ingredient |
| DE10064997A1 (de) | 2000-12-23 | 2002-06-27 | Merck Patent Gmbh | Benzoylpyridazine |
| US20080051428A1 (en) | 2002-05-15 | 2008-02-28 | Davis Paul J | Pyrroloquinoline quinone drugs and methods of use thereof |
| US7351692B2 (en) | 2002-06-19 | 2008-04-01 | The Board Of Trustees Of The University Of Illinois | Method and composition for potentiating the antipyretic action of a nonopioid analgesic |
| AU2003289440A1 (en) | 2002-12-25 | 2004-07-22 | Kissei Pharmaceutical Co., Ltd. | Nitrogen-containing heterocycic derivatives, medicinal compositions containing the same and medicinal use thereof |
| ATE405827T1 (de) | 2003-09-11 | 2008-09-15 | Takeda Pharmaceutical | Screening-verfahren |
| DE10352511A1 (de) | 2003-11-07 | 2005-06-16 | Ernst-Moritz-Arndt-Universität Greifswald | Verwendung von MRP4-Inhibitoren zur Behandlung und/oder Prophylaxe kardiovaskulärer Erkrankungen |
| US20050182011A1 (en) | 2003-11-13 | 2005-08-18 | Eric Olson | Inhibition of TRP channels as a treatment for cardiac hypertrophy and heart failure |
| KR20060124712A (ko) | 2004-02-20 | 2006-12-05 | 노파르티스 아게 | 신경퇴행 및 인지 장애를 치료하기 위한 ｄｐｐ ⅳ 억제제 |
| AU2005219776B2 (en) | 2004-03-04 | 2010-07-08 | Kissei Pharmaceutical Co., Ltd. | Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs |
| US20070185197A1 (en) | 2004-03-31 | 2007-08-09 | Hideki Fujikura | Phenol derivative, medicinal composition containing the same, and medicinal use thereof |
| EP2068879A2 (en) | 2006-05-02 | 2009-06-17 | Medical Technology Acceleration Program, Inc. | Pyrroloquinoline quinone drugs and methods of use thereof |
| JP2009149534A (ja) | 2007-12-18 | 2009-07-09 | Japan Health Science Foundation | Ｔｒｐｖ２阻害剤，疾患の予防又は治療剤，薬剤探索用リード化合物，及び薬剤探索方法 |
| KR100951656B1 (ko) | 2008-02-25 | 2010-04-07 | 고려대학교 산학협력단 | 프로베네시드를 포함하는 ｔｒｐｖ２ 활성제 |
| EP2317995B1 (en) | 2008-07-17 | 2016-12-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Inhbitors of mrp4 and agents stimulating mrp4 activity for the treatment of cardiac disorders |
| US8173690B2 (en) | 2008-09-04 | 2012-05-08 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
| EP2427056A4 (en) | 2009-05-07 | 2012-08-22 | Univ Cincinnati | METHODS FOR PREVENTING ISCHEMIC LESION BY STIMULATION OF PERIPHERAL NICE PERIPHERAL |
| US10806711B2 (en) * | 2011-08-12 | 2020-10-20 | University Of Cincinnati | Method of treating acute decompensated heart failure with probenecid |
-
2014
- 2014-03-13 AU AU2014244053A patent/AU2014244053B2/en active Active
- 2014-03-13 JP JP2016502000A patent/JP2016512564A/ja active Pending
- 2014-03-13 CA CA2904671A patent/CA2904671C/en active Active
- 2014-03-13 EP EP14722431.5A patent/EP2968238A1/en active Pending
- 2014-03-13 US US14/771,536 patent/US10583103B2/en active Active
- 2014-03-13 WO PCT/US2014/025930 patent/WO2014160153A1/en not_active Ceased
- 2014-03-13 MX MX2015012547A patent/MX376077B/es active IP Right Grant
-
2020
- 2020-12-08 JP JP2020203311A patent/JP2021042248A/ja active Pending
-
2023
- 2023-11-20 JP JP2023196822A patent/JP2024009140A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20160008305A1 (en) | 2016-01-14 |
| CA2904671C (en) | 2022-08-30 |
| US10583103B2 (en) | 2020-03-10 |
| MX2015012547A (es) | 2016-02-10 |
| CA2904671A1 (en) | 2014-10-02 |
| EP2968238A1 (en) | 2016-01-20 |
| JP2021042248A (ja) | 2021-03-18 |
| JP2024009140A (ja) | 2024-01-19 |
| AU2014244053B2 (en) | 2018-08-30 |
| JP2016512564A (ja) | 2016-04-28 |
| WO2014160153A1 (en) | 2014-10-02 |
| AU2014244053A1 (en) | 2015-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015012547A (es) | Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2. | |
| CO2019005236A2 (es) | Métodos para tratar afecciones inflamatorias | |
| MX2017005875A (es) | Metodos para tratar enfermedades oculares. | |
| CY1125247T1 (el) | Μεθοδοι θεραπειας καταθλιψης χρησιμοποιωντας ανταγωνιστες υποδοχεα ορεξινης-2 | |
| BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
| CL2017002526A1 (es) | Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares (divisional de solicitud n°2485-2015) | |
| MX2019010994A (es) | Metodos para tratar enfermedades y trastornos mediados por el complemento. | |
| BR112016000546A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
| MX2017000627A (es) | Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
| CO2022004902A2 (es) | Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer | |
| EA201790195A1 (ru) | Способы лечения рака с применением ингибиторов tigit и противораковых агентов | |
| EA201790398A1 (ru) | Способы лечения заболевания печени | |
| UY35313A (es) | Antiadhesion de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3 | |
| BR112017006113A2 (pt) | combinações sinérgicas de auristatina | |
| EA201890891A1 (ru) | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение | |
| MX2015008777A (es) | Crenolanib para el tratamiento de trastornos proliferativos que tienen flt3 mutado. | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| CO2020008863A2 (es) | Biomarcadores de tolerancia inmunitaria inducida por metotrexato | |
| BR112017002637A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
| EA201400002A1 (ru) | Способы лечения заболеваний сетчатки | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| NI201200085A (es) | Método para tratar la insuficiencia cardíaca con péptidos tipo estrescopina | |
| EA201790563A8 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
| WO2019118779A3 (en) | Peptides and other agents for treating pain and increasing pain sensitivity | |
| AR098832A1 (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |